You are here

Promacta (Eltrombopag) Submitted to FDA for Treatment of Severe Aplastic Anemia

Drug is currently approved for thrombocytopenia (February 28)

A supplemental new drug application (sNDA) has been submitted to the FDA for Promacta (eltrombopag, GlaxoSmithKline) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have shown an insufficient response to immunosuppressive therapy (IST).

SAA is a rare disorder in which the bone marrow fails to produce enough new blood cells. There are no approved therapies for SAA patients who are unresponsive to IST. Of those patients, approximately 40% die from infection or bleeding within 5 years of their diagnosis.

On February 3, 2014, the FDA granted a “breakthrough therapy” designation for eltrombopag in SAA.

The sNDA application was based on positive results from an open-label, phase II National Institute of Health study of eltrombopag in 43 heavily pretreated SAA patients with an insufficient response to IST.

Promacta (eltrombopag) is currently approved in the U.S for the treatment of patients with chronic immune (idiopathic) thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The drug is not approved for use in SAA.

Source: GlaxoSmithKline; February 28, 2014.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug